Health Canada's Plan to Simplify Natural Health Product Licensing: What NHP Companies Can Expect and How to Prepare

Health Canada is moving to make natural health product (NHP) rules lighter and more risk-based. As part of the federal Red Tape Review, the Department has committed to simplify both the requirements to license an NHP and the obligations that apply after a product is on the market. The stated goals are to reduce barriers for business, encourage more products into the Canadian market, and keep oversight proportionate to risk. This article explains what is changing, when, and how NHP companies should position themselves now.

Executive summary

What it is: A commitment in Health Canada and the Public Health Agency of Canada's Report on Red Tape Reduction (8 September 2025) to amend the Natural Health Products Regulations so that application requirements and post-authorization obligations for NHPs are simpler and more risk-based.
Status: Early stage. A pre-consultation notice of intent is anticipated for spring 2026, draft NHPR amendments are expected in the Canada Gazette, Part I in fall 2026 to winter 2027, and final publication is targeted for 2028.
Direction of travel: Streamlined or notification-based pathways for lower-risk products, simpler applications, flexible and risk-based post-market vigilance, more flexible labelling, and greater use of international reliance.
The catch: Nothing has changed yet. The NHPR still applies in full, GMP under GUI-0158 stays in force, and Vanessa's Law enforcement powers are unchanged.
Bottom line: The direction is positive, but the benefit will depend on how the reforms are designed and implemented. Companies that segment their portfolio by risk, keep strong systems, and engage in the consultations will be best placed to gain.

Why this matters now

Natural health products are a large and trusted part of the Canadian market. They include vitamins, minerals, herbal remedies, probiotics, homeopathic medicines, and many everyday self-care products. Every one of them is regulated under the Natural Health Products Regulations, which came into force on 1 January 2004 and created a distinct category for NHPs with tailored rules for safety, efficacy, and quality.

Over the past few years, industry has told Health Canada that the rules have become heavier. New enforcement powers, updated labelling requirements, and proposed cost recovery all added obligations. Many companies argued that the same rules were being applied to a low-risk vitamin and a more complex formulation alike, so the level of oversight no longer matched the level of risk. Health Canada has acknowledged this concern directly.

The Red Tape Review is the Government of Canada's response. For NHPs, it points toward a lighter, more risk-based system. For NHP companies, this is a genuine opportunity to bring products to market faster and at lower cost, but only if you prepare for a model that rewards clean evidence, mature quality systems, and disciplined post-market practices. That is where regulatory strategy, and expert support, make the difference.

Where things stand now

Quick answer: The plan is a commitment, not yet a rule. Health Canada published its intent in September 2025, a pre-consultation notice of intent is expected in spring 2026, draft regulations are expected in the Canada Gazette, Part I in fall 2026 to winter 2027, and final regulations are targeted for 2028. Until then, the current NHPR applies without change.

This is an important point for planning. Announcements about reducing red tape do not change your obligations. Your product licences, site licence, records, labelling work, and post-market duties all continue exactly as they are today. The value of acting now is preparation, not early relief.

What is Health Canada's NHP simplification plan?

Quick answer: It is a set of proposed amendments to the Natural Health Products Regulations, committed to in the Report on Red Tape Reduction, that would simplify how NHPs are licensed and what is required after licensing, while keeping oversight proportionate to risk.

The regulator for NHPs is the Natural and Non-prescription Health Products Directorate (NNHPD), which authorizes NHPs and non-prescription drugs for sale in Canada. In its plan, Health Canada states that the changes will simplify both application requirements and post-authorization obligations for NHPs, give industry more flexibility, encourage more products into the Canadian market, and support flexible, risk-based post-authorization vigilance. The Department has said it plans to amend the NHPR to reduce regulatory burden for both industry and government, while maintaining oversight proportionate to both risk and uncertainty.

Why is Health Canada doing this?

Health Canada has heard from industry that recent initiatives aimed at strengthening NHP oversight increased regulatory burden and did not align the level of oversight with the level of risk the products represent. The NHPR applies to a wide range of products with very different risk profiles, yet all are subject to the same rules. The reform sits inside a broader modernization program organized around themes that include international alignment, better service delivery, risk-based regulating, simpler rules and greater flexibility, and enabling new products.

The current NHP framework: why it feels heavy

Quick answer: Today, every NHP needs a product licence regardless of risk, applications follow set evidence rules, a site licence and GMP are required to make or import product, and post-market obligations apply across the board. The reform aims to make these steps lighter for lower-risk products.

To sell an NHP in Canada, a company needs a product licence, which is issued after a product licence application (PLA) and comes with a natural product number (NPN). Applications fall into classes based on how well the product matches Health Canada's pre-cleared monographs, ranging from compendial applications that follow a monograph to non-compendial applications that require full supporting evidence. To manufacture, package, label, or import an NHP, a company also needs a site licence, and it must meet the good manufacturing practices set out in GUI-0158, now at Version 4.0. After a product is licensed, changes are managed through amendments and notifications, and companies carry post-market duties such as adverse reaction reporting. Health Canada also holds strong enforcement powers over NHPs, including the ability to order recalls.

The table below shows how the current requirements line up against the direction of the reform.

Area	Today	Direction of the reform
Product licensing	Every NHP needs a product licence (NPN) through a PLA, regardless of risk level	Streamlined or notification-based pathways for lower-risk products
Application evidence	Compendial and non-compendial applications with set evidence and monograph requirements	Simpler application requirements, proportionate to risk
Renewals and registration	Ongoing obligations tied to the licence	Exempting low-risk products from registration and eliminating unnecessary renewals
Post-market obligations	Broadly similar rules across risk levels, plus Vanessa's Law powers	Flexible, risk-based post-authorization vigilance
Labelling	2022 Product Facts Table rules, current compliance date 21 June 2028	More flexible labelling, greater use of digital labelling, and a new transition period beyond 2028
Site licensing and GMP	Site licence plus GMP under GUI-0158 Version 4.0	Maintained, with oversight proportionate to risk
International access	Domestic review	Greater international alignment, reliance, and work-sharing

What is likely to change

Quick answer: Expect a lighter, tiered system. Lower-risk products may move to streamlined or notification-based licensing, applications should get simpler, post-market vigilance should become risk-based, labelling should become more flexible, and reliance on trusted foreign regulators should expand.

Based on Health Canada's published plan and departmental priorities, these are the changes NHP companies should anticipate:

A risk-based, tiered licensing model. Health Canada has signalled streamlined or notification-based approaches for lower-risk products, which would reduce review timelines and administrative work for well-established products.
Simpler applications. Application requirements are expected to become lighter and more proportionate, so a low-risk product does not carry the same burden as a novel, higher-risk one.
Fewer standing obligations. Departmental plans point to exempting low-risk products from registration and eliminating unnecessary renewals, which reduces ongoing paperwork.
Risk-based post-market vigilance. Post-authorization obligations should shift toward a model that focuses oversight where risk and uncertainty are higher.
More flexible labelling. Health Canada has committed to amend the NHPR labelling requirements to make them more flexible, with draft amendments targeted for spring 2027 and a new transition period beyond the current 21 June 2028 compliance date. Alternative flexibilities, simplified requirements, and digital labelling are all being explored.
Greater international alignment and reliance. Health Canada is expanding the use of reliance and work-sharing with trusted regulators, which can open faster routes to the Canadian market for products already reviewed abroad.

What will not change

Quick answer: The core protections stay. Safety, efficacy, and quality standards remain, GMP under GUI-0158 stays in force, site licensing continues, post-market vigilance continues in a risk-based form, and Health Canada keeps its enforcement powers, including recalls.

It is a mistake to read simplification as the removal of oversight. Health Canada has been explicit that it wants oversight proportionate to risk, not absent. That means:

Product standards remain. Safety, efficacy, and quality are still the foundation of the NHPR.
GMP is not being relaxed. The updated GMP guide, GUI-0158 Version 4.0, is in force and applies across manufacturers, importers, distributors, and contract partners.
Post-market responsibility grows, not shrinks. Modernization places more emphasis on lifecycle accountability, including evidence, claims substantiation, and post-market monitoring.
Enforcement powers stay. Health Canada retains its authority to require recalls and to act on unsafe products.

Will the reform deliver real relief?

Quick answer: That is the open question. The direction is positive, but industry has cautioned that streamlining front-end review will only help if it also reduces the underlying evidence, labelling, and post-market burden, and if Health Canada improves how it applies the rules in practice.

An honest assessment matters here. Some industry voices have welcomed the plan while warning that reforms could deliver only modest relief if they reduce review timelines without addressing total compliance cost. A streamlined pathway that keeps the same evidence, labelling, and post-market requirements would have limited impact. Industry has also pointed to what it calls hidden red tape, meaning burden that comes not from the regulation itself but from how it is implemented, including inconsistent evidence decisions and unpredictable review processes.

What the sector is watching for is concrete: licensing reforms that cut both time and cost, a genuine modernization of labelling that prioritizes flexibility, greater consistency and transparency in evidence requirements, operational improvements within Health Canada, and enforcement that addresses cross-border disparities. For your business, the practical takeaway is to prepare for the upside while planning for the possibility that early changes are incremental.

What NHP licence holders should do now

Quick answer: Segment your portfolio by risk, keep every current obligation in good standing, strengthen your evidence and quality systems, and engage in the consultations. The companies that prepare will move fastest when the new pathways open.

Below is a practical readiness sequence.

Map your portfolio by risk and licensing class. Identify which of your products are well-established and lower-risk, and which are novel or higher-risk. You cannot target a future notification pathway you have not mapped.
Track the file. Watch for the spring 2026 pre-consultation notice of intent and the Canada Gazette, Part I draft amendments expected in fall 2026 to 2027.
Keep every obligation current. Product licences, your site licence, records, and reporting all continue until the regulations change. Do not let anything lapse in anticipation of reform.
Do not pause labelling work. The 21 June 2028 compliance date and the label format may change, but the direction is set. Keep planning, and build in flexibility.
Strengthen evidence and claims files. A risk-based system puts more weight on defensible, traceable evidence. Clean claims substantiation will speed reviews and reduce questions.
Mature your quality system and GMP. GUI-0158 Version 4.0 is in force and is not being relaxed. Strong documentation, supplier oversight, and CAPA effectiveness are central.
Build risk-based post-market vigilance. Put in place a proportionate process for adverse reaction reporting, complaints, and recalls, so you are ready for a lifecycle model.
Identify reliance and international opportunities. For products already authorized by trusted foreign regulators, watch for reliance and work-sharing routes that could speed Canadian entry.
Engage through your industry association. Use consultation windows, including through associations such as the Canadian Health Food Association, to shape the outcome.

Readiness checklist

Use this as a pre-reform readiness check:

Portfolio segmented by risk level and NHP licensing class
Spring 2026 notice of intent and Part I comment period on your calendar
All product licences, the site licence, records, and reporting current
Labelling compliance work continuing toward 21 June 2028 with flexibility built in
Evidence and claims substantiation files reviewed and strengthened
Quality system and GMP aligned with GUI-0158 Version 4.0
Risk-based post-market vigilance process in place
Candidate products identified for a future notification pathway or reliance route
Industry association engagement planned for upcoming consultations
Cost and time impact of possible streamlining modelled for your pipeline

Common mistakes to avoid

These are the errors most likely to catch NHP companies out during this transition:

Assuming simplification is already in effect. It is not. The NHPR applies in full until it is amended.
Pausing labelling compliance. The 2028 date and format may shift, but the obligation remains. Stopping now risks a scramble later.
Reading less red tape as less accountability. Oversight is becoming more risk-based and lifecycle-focused, not absent.
Weak evidence or claims substantiation. Risk-based review rewards clean, defensible evidence and penalizes gaps.
Neglecting GMP and site licensing. GUI-0158 Version 4.0 is in force and unchanged by this reform.
Ignoring post-market duties. Adverse reaction reporting, complaints handling, and recall readiness all continue.
Missing consultation windows. The spring 2026 notice of intent and the Part I comment period are your chance to shape the rules.
Assuming faster review means lower cost. If evidence, labelling, and post-market rules stay, total cost may not fall as much as hoped.
Poor portfolio segmentation. Without a clear risk map, you cannot take advantage of a tiered pathway.
Overlooking international routes. Reliance and alignment could open faster entry for products already reviewed abroad.

Timeline and next steps

Quick answer: Health Canada committed to the reform in September 2025. A notice of intent is expected in spring 2026, draft NHPR amendments in the Canada Gazette, Part I in fall 2026 to winter 2027, labelling amendments in spring 2027, and final regulations targeted for 2028.

Date	Milestone
1 January 2004	Natural Health Products Regulations come into force
8 September 2025	Health Canada and the Public Health Agency of Canada publish the Report on Red Tape Reduction, committing to simplify NHP rules
Spring 2026 (expected)	Pre-consultation notice of intent anticipated
Fall 2026 to winter 2027 (expected)	Draft NHPR amendments pre-published in the Canada Gazette, Part I
Spring 2027 (expected)	Draft amendments to make NHP labelling more flexible, with a new transition period beyond 21 June 2028
2028 (targeted)	Final regulations published in the Canada Gazette, Part II

The coming eighteen months are preparation time. The direction is set, but the detail, including which products qualify for lighter pathways and exactly how post-market obligations change, will arrive with the consultation and the draft regulations. Companies that build their risk map and strengthen their systems now will be ready to move the moment the new pathways open. This reform also sits alongside Health Canada's broader push toward international reliance, which you can explore in our analysis of the Foreign Reliance Order for drugs.

How MFLRC can help

Quick answer: MFLRC helps natural health product companies prepare for a risk-based licensing model, from portfolio risk mapping and licensing strategy through quality systems, evidence, and post-market readiness.

Reform rewards preparation, and preparation is what we do. With more than 20 years of Quality Assurance and Regulatory Affairs experience across natural health products, pharmaceuticals, food, and cannabis, MFLRC provides senior-led, practical guidance rather than generic checklists. We can support you across the full lifecycle:

Licensing strategy and applications. We assess your portfolio, map products to the right licensing class, and prepare product licence applications, as part of our regulatory affairs, licensing, and import and export support. Explore our natural health products regulatory support.
Quality systems and GMP. Strong quality documentation is central to a risk-based model. Our quality assurance services cover quality management systems, SOPs, records, and stability planning, aligned with the GMP expectations in our guide to GUI-0158 Version 4.0 for NHPs.
Gap assessments and audit readiness. We identify weaknesses before Health Canada does, through our audit services, including gap analyses and mock inspections.
Evidence and claims support. We help you build defensible evidence and claims files that hold up under a more risk-based, evidence-focused review.
Post-market and lifecycle compliance. We help you build proportionate post-market vigilance, from adverse reaction reporting to recall readiness. For a broader view of your obligations, see our overview of NHP compliance in Canada.

Whether you are launching your first NHP or expanding an established portfolio, we help you turn regulatory change into an advantage. Book a consultation to discuss your products and pathway.

Book a Consultation

Frequently asked questions

What is Health Canada's plan to simplify NHP licensing?

It is a set of proposed amendments to the Natural Health Products Regulations, committed to in the September 2025 Report on Red Tape Reduction, that would simplify both the requirements to license an NHP and the obligations that apply after licensing, while keeping oversight proportionate to risk.

When will the changes take effect?

Not immediately. A pre-consultation notice of intent is anticipated for spring 2026, draft regulations are expected in the Canada Gazette, Part I in fall 2026 to winter 2027, and final regulations are targeted for the Canada Gazette, Part II in 2028. The current rules apply until then.

Will every NHP still need a product licence?

That is under review. Health Canada has signalled streamlined or notification-based pathways for lower-risk products, which could reduce or change the requirements for well-established products. Nothing is decided, and higher-risk products are likely to keep fuller requirements.

Does this change the June 2028 NHP labelling compliance date?

Health Canada plans to amend the labelling requirements to make them more flexible, with draft amendments targeted for spring 2027 and a new transition period beyond 21 June 2028. The final revised date has not been announced, so companies should keep planning while building in flexibility.

Will GMP and site licensing be relaxed?

No. The GMP guide GUI-0158 Version 4.0 and site licensing remain in force. Health Canada's aim is oversight proportionate to risk, not the removal of quality requirements.

Why is Health Canada reducing NHP red tape?

Industry told Health Canada that recent measures increased burden and did not match oversight to risk. The reform, part of the federal Red Tape Review, aims to reduce barriers, encourage more products into the market, and keep oversight proportionate to risk and uncertainty.

Will this make it easier to bring products to the Canadian market?

That is the stated goal. Industry is watching to ensure the changes deliver real reductions in both time and cost, rather than only faster front-end review.

What should NHP companies do now?

Segment your portfolio by risk, keep every current obligation in good standing, strengthen your evidence and quality systems, continue labelling work, and engage in the consultations. Preparing now means you can move quickly when the new pathways open.

Conclusion

Health Canada's plan to simplify natural health product licensing is one of the most encouraging signals the sector has had in years. It points toward a system where a low-risk vitamin is not treated like a novel, higher-risk product, and where well-prepared companies can reach the Canadian market faster. The opportunity is real.

The opportunity also favours the prepared. The rules have not changed yet, the detail is still to come, and the benefit will depend on how the reforms are designed and applied. Companies that map their portfolio by risk, keep their licences and quality systems in good standing, and engage in the consultations will be ready to move the moment the new pathways open.

Want help preparing your NHP portfolio for a risk-based licensing model, or getting your quality and evidence systems ready? Contact MFLRC for senior regulatory guidance tailored to your business.